Connect with us


Germany: Insurers reimburse 123 million to medical cannabis patients



Insurers reimbursements to German patients with medical cannabis prescriptions reached a new record in the period from October to December 2019, advanced the German National Association of Health Insurance Funds (National Association of Statutory Health Insurance Funds). According to recently released data, insurers have increased the value of reimbursements to more than 120 million euros, reported this week to MJBizDaily.

despite some supply problems at the end of 2019, medical cannabis reimbursements reached €36.6 million in the fourth half of 2019, an increase of more than 13% compared to the previous semester, in which medical cannabis reimbursements totaled €32,3 million. The reason for this increase is directly related to the increase in prescriptions dispensed in Germany, which rose by 40% annually.

Insurers – which cover around 90% of the German population – reimbursed around 123 million euros in 2019, in line with the around 120 million euros forecast by the Marijuana Business Daily in December, when data for the last semester of the year were still unknown.

The numbers:

  • The 123 million euros reimbursed in 2019 represents an increase of 67% compared to the 74 million euros reimbursed in 2018.
  • German pharmacies registered 267 prescriptions through the legal program in 348, 2019% more than the 44 prescriptions that had been registered the previous year.

This increase in the absolute value in relation to the number of prescriptions indicates that physicians issued, on average, prescriptions for larger quantities. Since the new regulatory framework was implemented in 2017, reimbursements reached a new record in December 2019, reaching 13 million euros in that month alone. Also in December, 6,6 million euros were reimbursed, 14% more than in November, where around 5,8 million euros of patient expenses were covered by German insurers.

The articles of the Canadian producer 'Aurora Cannabis' became unavailable in the last days of November. However, the increase in reimbursements in December for products consisting of cannabis flowers suggests that German patients who used Aurora flowers found an alternative in market competitors.

the tmarket tomorrow

All reimbursement data is based on retail prices of pharmacies, which are the only authorized points of sale in Germany, while for products not included in the category of “finished pharmaceutical products”, the percentage increase in the price of the products by pharmacies could reach the 100%.

the german government acknowledged earlier this month, in response to a parliamentary inquiry, which does not know the amount of cannabis sold in Germany in 2019, as it does not have data on private prescriptions.

Another way to access the full size of the German market is through import data, because so far Germany depends exclusively on international suppliers for most of its products, including flowers. In 2019, there were imported to Germany a total of 6 kilograms of flowers, which according to the German government are “mainly for distribution in pharmacies.”

Product range

Germany remains by far the largest importer of medical cannabis in the world and its domestic flower production should not reach the market before October 2020. By the end of 2019 all full spectrum flowers and extracts were imported from Canada, the Netherlands or Portugal. The flower, which includes the categories “unprocessed flower” and “flower used in preparations,” typically sold as crushed flower, accounts for just over half of the total medical cannabis market, accounting for about 51% of total reimbursement of cannabis during the fourth semester of 2019, similar to the 52% it represented in the previous semester.

Reimbursement of full spectrum extracts grew slightly, but amounted to only 4% of the reimbursed market. Coverage of cannabinoid preparations has increased slightly since the previous semester, now standing at 30% of the market covered by insurance.

The category is mainly represented by Dronabinol, manufactured in Germany by C3 – a subsidiary of Canada's Canopy Growth – which also includes pharmaceutical CBD, supplied to pharmacies by several companies, which sell it exclusively on presentation of a medical prescription.

Reimbursements for finished pharmaceuticals, a category primarily represented by Sativex, decreased slightly from the previous half year to 15% in the second half of 2019.

Featured Image: National Cancer Institute on Unsplash

Click here to comment
Notify of
Inline feedback
View all comments

Watch the Documentary "Patients"

Documentary Patients Laura Ramos help us grow

Mais recentes

Interviews1 hours ago

Luio Zau: “My hobby is painting. Now my job is to be spectacular.”

Luio Zau, creative genius, alter ego of Portuguese artist Luís Miguel Freire Estevinho, born in 1981. The restless spirit has already...

Events2 days ago

Mini Binoides Festival takes place on October 14th in Lisbon

The first edition of the Mini Festival Binoides, an event dedicated to cannabis culture, will arrive in Lisbon next...

Hemp3 days ago

Obelisk Farm at Greenfest Braga '23 with Hemp paper Workshop

Industrial hemp is present at Greenfest Braga '23, through a workshop on hemp paper, taught by...

International4 days ago

The role of endocannabinoids in the brain's stress relief mechanism

In the realm of medical science, groundbreaking discoveries have the power to revolutionize the healthcare landscape. Recently,...

International5 days ago

Netherlands prepares to launch pilot cannabis sales project

Contrary to what many people think, cannabis is still not legal in the Netherlands and the country is...

Press Releases6 days ago

Portugal: GreenBe Pharma obtains authorization to cultivate cannabis for medicinal purposes

GreenBe Pharma, a pharmaceutical specialist in cultivation, has obtained GACP authorization, granted by the National Authority for Medicines and Products...

Press Releases6 days ago

Portugal: SOMAÍ receives EU-GMP certification and obtains €5 million in financing

SOMAÍ Pharmaceuticals Unipessoal LDA, the largest European manufacturer of pharmaceutical cannabis products, is pleased to announce that...

Events7 days ago

Portugal: 3rd edition of Medical Cannabis Europe takes place in Lisbon this Thursday and Friday

With more than 25 renowned national and international speakers in the area of ​​medicinal cannabis, the third edition of Medical Cannabis...

International1 weeks ago

Spain: Is indoor cannabis cultivation responsible for electrical outages in Andalusia?

More than 50.000 Spaniards have recently suffered cuts in electricity supply, lasting more than 48 hours in some cases....

Events2 weeks ago

Cognoscitiva's 20th anniversary party is this Saturday, in Lisbon

Cognoscitiva celebrates 20 years of existence with a party at the Benfica store, this Saturday, September 23rd,...